The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 ...

The Cancer Pioneers” has just dropped, giving audiences a moving first look at the groundbreaking new documentary that ...

May 1, 2025GeoVax Labs, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.59. Operator: Good afternoon. And welcome everyone to the GeoVax First Quarter 2025 Corporate ...

Clinical Trials in India have gained global attention for their rapid growth, world-class infrastructure, and access to a diverse patient population. With increasing support from regulatory bodies and ...

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be ...

The Department of Health and Human Services said it is redirecting funding from what it calls a wasteful Biden-era project on ...

Fulcrum Therapeutics, Inc. ( NASDAQ: FULC) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Alex Sapir – President and Chief Executive Officer Alan Musso – Chief Financial Officer Iain Fraser – ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

Lexeo Therapeutics, Inc.’s LXEO share price has surged by 9.41%, which has investors questioning if this is right time to ...

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to ...

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

Tharimmune, Inc., (NASDAQ:THAR) (”Tharimmune” or the “Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, today announced ...